989 East Hillsdale Blvd.
Tel: (650) 209-4055
About Apollomics, Inc.
Apollomics, Inc. is an innovative biopharmaceutical company committed to bridging innovation from East and West to discover and develop oncology combination therapies that harness the immune system and target specific molecular pathways to defeat cancer globally. Apollomics’ existing pipeline consists of development-stage assets including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.
49 articles with Apollomics, Inc.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics
CBT Pharma presented preclinical data which showed that CBT-502 efficiently inhibited binding of PD-L1 with no binding to PD-L2, CD28, ICOS or CTLA4.
CBT Pharma Announces First U.S. Patient Dosed In Phase 1 Clinical Trial Of C-Met Inhibitor, CBT-101, For Advanced Solid Tumors With C-Met Dysregulation
CBT Pharma today announced that the first subject has been dosed in the Phase I multi-center study, CBT-101-01 which is an important milestone for CBT and its employees.
CBT Pharma Appoints Nationally Recognized Leaders In Oncology To Newly Established Scientific Advisory Board
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity Of Its Highly Specific C-MET Inhibitor, Bozitinib (CBT-101), At AACR Annual Meeting 2017
CBT Pharma Release: First-in-Human Genolimzumab Phase I Study Initiated To Assess Safety And Preliminary Efficacy In Patients With Select Advanced Solid Tumors
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity Of Its Programmed Death-1 Antibody, CBT-501, At ASCO-SITC Clinical Oncology Symposium
Bay Area’s CBT Pharma Plans to Launch 2 Phase I Trials in 2017
CBT Pharma Closes $9.75 Million Series A Financing Led By OrbiMed For Development Of Oncology Pipeline